justbacked

Biotechnology, Health Care, Medical, Therapeutics

Triveni Bio

Triveni Bio raised $65M in a Series C announced on Jun 17, 2026, led by Janus Henderson Investors, Goldman Sachs, Polaris Partners, OrbiMed, Cormorant Asset Management. Since then it has posted 12 roles (7 still open), the first 30 days after it. Another 1 open role was posted before the announcement. With 8 open roles it is hiring more than 13% of the 83 Series C startups on JustBacked (median: 22). In total it has raised $272M over 3 rounds from 14 investors.

Roles posted per month since the round
  • July 20262
  • August 20261
  • September 20262
  • October 20263
  • November 20264

From Triveni Bio's own hiring system, by posting date. Tracked since Aug 21, 2026; roles that closed before then aren't counted.

Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.

Why join Triveni Bio?

The bet: Triveni Bio's bispecific antibody can treat the root cause of atopic dermatitis and reach patients that current approaches leave behind. If it pays off, this Watertown biotech could redraw treatment for a common skin disease and reach other immune conditions. Its first patient is dosed in a global Phase 2 study of TRIV-573, backed by $272M across three rounds and a $65M Series C lighter than most at its stage.

JustBacked's take, based on Triveni Bio's own site and its funding and hiring data.

Series C · $65M · 157d agotriveni.bio

Hiring velocity

Open roles
8
Added, 30 days
+5
Added, 7 days
+1
Closed, 30 days
2
Raised
157 days ago
Led by
Janus Henderson Investors, Goldman Sachs, Polaris Partners, OrbiMed, Cormorant Asset Management
Team size
11-50
HQ
Watertown, Massachusetts, United States
Newest role
1d ago
Tracked since
Aug 21, 2026

Where they're hiring

Clinical4
Science2

Open roles at Triveni Bio

Source: triveni.bio, checked daily.